• Something wrong with this record ?

The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence

L. Czupryniak, D. Dicker, R. Lehmann, M. Prázný, G. Schernthaner

. 2021 ; 20 (1) : 198. [pub] 20211001

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc23004957

Patients with Covid-19 place new challenges on the management of type 2 diabetes, including the questions of whether glucose-lowering therapy should be adjusted during infection and how to manage a return to normal care after resolution of Covid-19 symptoms. Due to the sudden onset of the pandemic, physicians have by necessity made such important clinical decisions in the absence of robust evidence or consistent guidelines. The risk to patients is compounded by the prevalence of cardiovascular disease in this population, which alongside diabetes is a major risk factor for severe disease and mortality in Covid-19. We convened as experts from the Central and Eastern European region to consider what advice we can provide in the setting of type 2 diabetes and Covid-19, considering the evidence before, during and after infection. We review recommendations that have been published to date, and consider the best available-but currently limited-evidence from large observational studies and the DARE-19 randomized control trial. Notably, we find a lack of guidance on restarting patients on optimal antidiabetic therapy after recovering from Covid-19, and suggest that this may provide an opportunity to optimize treatment and counter clinical inertia that predates the pandemic. Furthermore, we emphasize that optimization applies not only to glycaemic control, but other factors such as cardiorenal protection. While we look forward to the emergence of new evidence that we hope will address these gaps, in the interim we provide a perspective, based on our collective clinical experience, on how best to manage glucose-lowering therapy as patients with Covid-19 recover from their disease and return to normal care.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004957
003      
CZ-PrNML
005      
20230425171823.0
007      
ta
008      
230418s2021 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12933-021-01389-1 $2 doi
035    __
$a (PubMed)34598700
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Czupryniak, Leszek $u Department of Diabetology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland. leszek.czupryniak@wum.edu.pl
245    14
$a The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence / $c L. Czupryniak, D. Dicker, R. Lehmann, M. Prázný, G. Schernthaner
520    9_
$a Patients with Covid-19 place new challenges on the management of type 2 diabetes, including the questions of whether glucose-lowering therapy should be adjusted during infection and how to manage a return to normal care after resolution of Covid-19 symptoms. Due to the sudden onset of the pandemic, physicians have by necessity made such important clinical decisions in the absence of robust evidence or consistent guidelines. The risk to patients is compounded by the prevalence of cardiovascular disease in this population, which alongside diabetes is a major risk factor for severe disease and mortality in Covid-19. We convened as experts from the Central and Eastern European region to consider what advice we can provide in the setting of type 2 diabetes and Covid-19, considering the evidence before, during and after infection. We review recommendations that have been published to date, and consider the best available-but currently limited-evidence from large observational studies and the DARE-19 randomized control trial. Notably, we find a lack of guidance on restarting patients on optimal antidiabetic therapy after recovering from Covid-19, and suggest that this may provide an opportunity to optimize treatment and counter clinical inertia that predates the pandemic. Furthermore, we emphasize that optimization applies not only to glycaemic control, but other factors such as cardiorenal protection. While we look forward to the emergence of new evidence that we hope will address these gaps, in the interim we provide a perspective, based on our collective clinical experience, on how best to manage glucose-lowering therapy as patients with Covid-19 recover from their disease and return to normal care.
650    _2
$a COVID-19 $x komplikace $7 D000086382
650    _2
$a diabetes mellitus 2. typu $x komplikace $x farmakoterapie $7 D003924
650    12
$a regulace glykemie $7 D000085002
650    _2
$a lidé $7 D006801
650    _2
$a hypoglykemika $x škodlivé účinky $x terapeutické užití $7 D007004
650    _2
$a inzulin $x terapeutické užití $7 D007328
650    _2
$a směrnice pro lékařskou praxi jako téma $7 D017410
650    _2
$a rizikové faktory $7 D012307
650    _2
$a časové faktory $7 D013997
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Dicker, Dror $u Department of Internal Medicine D, Hasharon Hospital, Rabin Medical Centre, Petah Tikva, Israel $u Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
700    1_
$a Lehmann, Roger $u Department of Endocrinology, Diabetes and Nutrition, University Hospital Zürich, Zürich, Switzerland
700    1_
$a Prázný, Martin $u 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University and General Faculty Hospital, Prague, Czech Republic
700    1_
$a Schernthaner, Guntram $u Department of Medicine I, Rudolfstiftung Hospital Vienna, 1030, Vienna, Austria. guntram@schernthaner.eu $u Medical University of Vienna, Vienna, Austria. guntram@schernthaner.eu $1 https://orcid.org/0000000323974468
773    0_
$w MED00008211 $t Cardiovascular diabetology $x 1475-2840 $g Roč. 20, č. 1 (2021), s. 198
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34598700 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425171819 $b ABA008
999    __
$a ok $b bmc $g 1925197 $s 1191166
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2021 $b 20 $c 1 $d 198 $e 20211001 $i 1475-2840 $m Cardiovascular diabetology $n Cardiovasc Diabetol $x MED00008211
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Archiving options